Finding Data to Assess Real World Effectiveness from Clinical Trials

 Finding Data for Assessing Real World Effectiveness from Clinical Studies

Models for health interventions have been developed based on statistically significant results from Randomized Control Trial experiments which are then observed in pragmatic patient controlled (PCT) trials. If the PCT process shows a positive intended effect the sponsoring organization promotes the results to a targeted medical community. However, Real World Clinical Results (RWR) do not match the control trials, because of patient demographic variables, comorbidities, and clinical practice differences. An evolving model of research and application of inquiry to clinical adaption is emerging, called Real World Effectiveness (RWE) which gauges the patient and medical practice value before rote adoption. A recent journal article by Franz Persolt, a medical doctor and an economist, Considerations for Stabilizing the Two Main Pillars of Healthcare: Finance and Nursing (Franz Perzsolt, 2026), reveals a new three-dimensional model to integrate RWE into the pragmatic trial process. By adhering to a model which reviews clinical practice norms and the fuller spectrum of patient risk, the RWE effectiveness is addressed. Before analyzing the effectiveness of this process, we need to find pragmatic clinical trials for which this concept would apply.

How Do We Find Real World Effectiveness Data

After searching for databases that include the RWE assessment post Pragmatic Trial, there is no resource which combines the PCT results and the economic outcomes of an intervention. This is essential for adoption of any treatment variance systemically. Having worked as a performance improvement analyst for a hospital group, I am familiar with the art of data mining. Assessing the results of clinical trials (PCT) is challenging because the Food and Drug Administration sets the rules and an astounding 45% of these studies are not required to show their results. The National Institutes of Health, despite the gargantuan Trump Administration budget cuts, still maintains the largest digital library of clinical trials, some 606,601 studies, from all 50 states and 226 countries.[1] The query I investigated was; Assessing the Impact on Patient Mortality by Reducing Invasive Procedures for Ductal Carcinoma In situ, a pre-metastatic breast cancer. I found seven studies on ductal carcinoma; one did not report study results, because the chief investigator left the university which provided grant funding and several studies had notes which indicated study results have not been submitted. I found a single study, from South Korea, which published its pragmatic trial results, but to read the document, I had to do a Google search, which led me to the open-access scientific journal, Springer.

Clinical Trial NC705561280

Selective Omission of Sentinel Node Biopsy in Mastectomy for Ductal Carcinoma in Situ, is an observational study over an eleven-year period, completed in 2023. (Bae, 2024) Clinical trial NC705561280, followed 385 women from 2010 to 2021 through Gagnam Severance Hospital, South Korea. The study compared the incidence of metastatic breast cancer for women who had suspicious auxiliary lymph nodes to those who lacked the suspicious node. The purpose of the investigation was to determine if it necessary to remove the sentinel lymph node for all women who are potentially at risk of metastatic breast cancer?

Study Results

Only 4.2% of patients had axillary lymph node metastasis, but for patients with a suspicious node, 13.5% tested positive for metastatic cancer. For patients without suspicious lymph nodes, only 1.7% tested positive for metastasis. The study also found that women under the age of 50 were significantly more likely to acquire invasive cancer, 13.5% versus 1.7% for women over the age of 50. Further, of the patients under 50 with suspicious lymph nodes in radiologic readings, 24.4% had metastatic breast cancer. This statistic is meaningful in the real world because it reveals the population for which the invasive radiologic procedure is most likely to benefit via early diagnosis of breast cancer risk. Early diagnosis means greater likelihood of survival. It also narrows the window for women who may require mastectomy, which reduces patient harm. And from a financial standpoint, mastectomies are expensive hospital procedures, so avoidance of twelve to fifty-five thousand dollars per unnecessary mastectomy leaves funding for other health interventions. This RWE analysis, thanks to good study design, shows no patient harms for avoidance of the procedure for specific populations and saves the health system money. The key to effective health surveillance is identification of those most at risk of invasive breast cancer, and early lymph node assessment.

In another study, the Sound Trial, followed 1,405 women with small invasive breast cancer (<2 cm) to assess whether it was necessary to remove the sentinel lymph node, if the biopsy is negative. The primary study outcome found 97.7% of women who were followed, with no axillary surgery on the node remained cancer free after five years. The reoccurrence rate was only .4%. (Oreste Davide Gentilini, Edoardo Botteri, & Claudia Sangalli, 2023) The RWE of this PCT was the refinement of who needed the sentinel node biopsy and removal, which reduced patient harm and expense, without adversely impacting mortality. Ergo-it reduces patient harm and incurs less cost for the health system.

Being able to answer the question- Is it worth it, economically and in terms of perception of value, health care organizations will be better able to target patient treatments. All countries would benefit by an earlier integration of the “Is it worth it” line of inquiry in evaluating pragmatic trial project funding and deployment of findings. Through adherence to a standard of inquiry and transparency regarding the applied results, health systems will more readily be able to gauge efficacy by region, by practice, and by patient. Incorporation of this model of analysis into university settings, policy analysis, and clinical practice could transform health systems globally.

And this is the healthpolicymaven signing off, encouraging you not to sign blanket releases, do stipulate that for which you agree and decline when undergoing a procedure or admission.

This article was written by healthcare journalist, Roberta Winter, who received no compensation from any sector of the healthcare industry. This article was written without assistance from artificial intelligence.

 References

Bae, S. K. (2024, April 12). Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates. Breast Cancer Res 26, 65 (2024). , 65. doi:https://doi.org/10.1186/s13058-024-01816-7

Franz Perzsolt, M. P. (2026, July 27). Considerations for Stabilizing the Two Main Pillars of Healthcare: Financing and Nursing. Toxicology and Applied Pharmacology Insites, 8(1), 01-09. Retrieved September 30, 2026

Oreste Davide Gentilini, M., Edoardo Botteri, P., & Claudia Sangalli, B. e. (2023, September 21). Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes. JAMA-Oncology, 2023;9(11), 1557-1564. doi:doi:10.1001/jamaoncol.2023.3759

 

---

[1] Clinicaltrials.gov